News

pharmaphorum3h
GSK's growth plans dented by Blenrep setback
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
Health Care Roundup: Market Talk
Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.
CNBCTV185h
Stock Crash: MNC drugmaker shares tank after key drug fails to get regulatory panel nod
According to reports, the USFDA's Oncologic Advisory Committee voted that the risks from the drug, called Blenrep, outweighed ...
KTBS 32h
Stocks up, dollar down tracking Trump moves and earnings
European and Asian stocks markets closed out the week broadly higher Friday following Wall Street's latest record highs ...
Fierce Pharma2d
As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
FTSE 100 Live 18 July: Reckitt Benckiser sells Cillit Bang, GSK shares slide
A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...
Explore more
FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage
Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...
Asianet Newsable on MSN8h
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay Optimistic
The median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...